We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
신규 편입 · 포트폴리오 비중 0.03%
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $200 · 21 analysts
Stored first · Google News · Yahoo Finance (English)
Insmed (INSM) After Insider Selling And Brensocatib Hopes What Does Valuation Say - simplywall.st
Insmed (INSM) After Insider Selling And Brensocatib Hopes What Does Valuation Say simplywall.st
Enterprise value to EBIT forward of Insmed Incorporated – BMV:INSM - TradingView
Enterprise value to EBIT forward of Insmed Incorporated – BMV:INSM TradingView
INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study - Stocktwits
INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study Stocktwits
What's Driving Insmed's Recent Volatility - Kavout | AI
What's Driving Insmed's Recent Volatility Kavout | AI
Insmed CEO William Lewis sells over $1.25m in company stock - Investing.com Australia
Insmed CEO William Lewis sells over $1.25m in company stock Investing.com Australia
Insmed Insider Sold Shares Worth $1,256,084, According to a Recent SEC Filing
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | After market close (AMC) | $-0.77 | — | — | $392.17M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $-1.42 | — | — | $92.82M | Reported |
| FY2025 Q3 | 2024. 09. 30. | Time TBD | — | $-4.27 | — | — | $259.27M | Reported |
| FY2025 Q2 | 2024. 06. 30. | Time TBD | — | $-3.02 | — | — | $165.84M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 05. 14. | Truist Securities | — | Maintain | Buy → Buy | — | Truist Securities: Buy |
| 2026. 05. 09. | RBC Capital | — | Maintain | Outperform → Outperform | — | RBC Capital: Outperform |
| 2026. 05. 08. | Wells Fargo | — | Maintain | Overweight → Overweight | — | Wells Fargo: Overweight |
| 2026. 05. 08. | Guggenheim | — | Maintain | Buy → Buy | — | Guggenheim: Buy |
| 2026. 04. 18. | Roth Capital | — | Maintain | Buy → Buy | — | Roth Capital: Buy |
| 2026. 04. 14. | RBC Capital | — | Maintain | Outperform → Outperform | — | RBC Capital: Outperform |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 962,156 | $167.45M | 0.26% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 237,017 | $38.76M | 0.03% | — | New position |